 The FDA has accepted for review Incyte Corporations NASDAQ: INCY supplemental marketing application seeking approval for ruxolitinib cream 1.5 Opzelura, a topical JAK inhibitor for vitiligo. Under the Priority Review, the application covers adolescents and adults over 12 years with vitiligo, a chronic autoimmune disease characterized by skin depigmentation. 